Physician profile
Robert L Lee
NPI 1366537482
$4,851.81
in general payments reported to CMS, 2019-2025
35 companies · $686 in 2025
The $686 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,293 · 2020: $813 · 2021: $1,291 · 2022: $103 · 2023: $211 · 2024: $454 · 2025: $686.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,351.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,351.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $797.55 | 2021-2025 | |
| Astrazeneca Pharmaceuticals Lp | $591.89 | 2019-2025 | Airsupra, Breztri |
| Amarin Pharma, INC. | $432.52 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $394.90 | 2019-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $344.15 | 2023-2025 | Caplyta |
| Lilly USA, LLC | $341.95 | 2019-2025 | Zepbound, Mounjaro |
| Allergan, INC. | $296.44 | 2019-2020 | |
| Novo Nordisk INC | $274.11 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Takeda Pharmaceuticals U.S.A., INC. | $201.82 | 2019-2021 | |
| Amgen INC. | $194.51 | 2019-2025 | Repatha, Otezla, Krystexxa |
| Glaxosmithkline, LLC. | $144.81 | 2019-2025 | Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $126.35 | 2019-2025 | Jardiance |
| Esperion Therapeutics, INC. | $83.57 | 2020-2025 | Nexletol |
| Janssen Pharmaceuticals, INC | $61.44 | 2019-2021 | |
| Pfizer INC. | $58.51 | 2019-2025 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $57.91 | 2019-2021 | |
| Eisai INC. | $53.63 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $50.17 | 2019-2020 | |
| Ethicon US, LLC | $41.18 | 2019-2021 | |
| Exact Sciences Corporation | $40.28 | 2025 | Cologuard Collection Kit |
| Kowa Pharmaceuticals America, INC. | $30.36 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $29.48 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $27.12 | 2020-2021 | |
| Otsuka America Pharmaceutical, INC. | $22.76 | 2025 | Rexulti |
| Vanda Pharmaceuticals INC. | $17.64 | 2025 | Fanapt |
| Nestle Healthcare Nutrition INC. | $17.44 | 2021 | |
| Si-Bone, INC. | $15.54 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.44 | 2021 | |
| Abbott Laboratories | $13.61 | 2021 | |
| Ibsa Pharma INC. | $13.10 | 2020 | |
| Vistapharm, INC. | $12.86 | 2021 | |
| Xeris Pharmaceuticals, INC. | $12.49 | 2022 | |
| Supernus Pharmaceuticals, INC. | $12.18 | 2022 | |
| Dexcom, INC. | $12.13 | 2021 | |
| Horizon Therapeutics Plc | $11.97 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.